Zhang Shaohui, Zhang Yuan-da, Dong Qing-Wei, Gu Fang
Shaohui Zhang, Department of Pediatric Medicine, Baoding Children's Hospital, Baoding 071000, Baoding, China.
Yuan-da Zhang, Department of Pediatric Medicine, Baoding Children's Hospital, Baoding 071000, Baoding, China Department of Pediatric Medicine, Baoding City Children Respiratory and Digestive Diseases Clinical Research Key Laboratory, Baoding 071000, Baoding, China.
Pak J Med Sci. 2020 Nov-Dec;36(7):1623-1627. doi: 10.12669/pjms.36.7.3048.
To compare curative effect and safety of omeprazole under different treatment courses in treatment of children with peptic ulcer (PU, diameter≤1.0cm) and helicobacter pylori (HP) infection and its influence on inflammatory cytokines.
The study was a randomized controlled study and conducted at Baoding children's hospital from June 2015 to June 2018. In this study 100 PU children with positive HP were chosen and classified into two groups at random. The 58 cases in the observation group were given omeprazole + amoxicillin + clarithromycin, and the antibiotics were not used two weeks later. Then, omeprazole was used to treat for two weeks. 42 cases in the control group were given omeprazole + amoxicillin + clarithromycin for two weeks. Curative effect, HP eradication rate, clinical symptoms, incidence of adverse reactions, level of serum inflammatory cytokine interleukin-6 (IL-6) and level of tumor necrosis factor-a (TNF-a) in two groups were compared.
Total effective rate, HP eradication rate and clinical symptom relief of observation group were better than those of control group, and the differences showed statistical significance (P>0.05). The differences of two groups in the incidence of adverse reactions had no statistical significance (P>0.05). Serum IL-6 level and TNF-a level of observation group were significantly lower than those of control group and before the treatment, and the differences had statistical significance (P>0.05).
The application of omeprazole in treatment of PU patients with positive HP for four weeks can significantly improve PU cure rate and HP eradication rate, relieve clinical symptoms and reduce inflammatory response, so it deserves to be promoted clinically.
比较不同疗程奥美拉唑治疗直径≤1.0cm的儿童消化性溃疡（PU）合并幽门螺杆菌（HP）感染的疗效、安全性及其对炎性细胞因子的影响。
本研究为随机对照研究，于2015年6月至2018年6月在保定市儿童医院进行。选取100例HP阳性的PU患儿，随机分为两组。观察组58例给予奥美拉唑+阿莫西林+克拉霉素，2周后停用抗生素，再用奥美拉唑治疗2周。对照组42例给予奥美拉唑+阿莫西林+克拉霉素治疗2周。比较两组的疗效、HP根除率、临床症状、不良反应发生率、血清炎性细胞因子白细胞介素-6（IL-6）水平和肿瘤坏死因子-α（TNF-α）水平。
观察组的总有效率、HP根除率和临床症状缓解情况均优于对照组，差异有统计学意义（P>0.05）。两组不良反应发生率的差异无统计学意义（P>0.05）。观察组血清IL-6水平和TNF-α水平均显著低于对照组及治疗前，差异有统计学意义（P>0.05）。
奥美拉唑应用于HP阳性的PU患儿治疗4周，可显著提高PU治愈率和HP根除率，缓解临床症状，减轻炎症反应，值得临床推广。
